chartexchange

BetterLife Pharma Announces New Preclinical Research Highlighting Neuroplasticity-Related Effects of Non-Hallucinogenic BETR-001 at Neuroscience 2026

GlobeNewswire Inc. | Nov 17, 2026 8:15 AM EST

Single-nucleus RNA sequencing identifies molecular responses overlapping with LSD, providing additional scientific support for BetterLife's planned BETR-001 clinical program Single-nucleus RNA sequencing identifies molecular responses overlapping with LSD, providing additional scientific support for BetterLife's planned BETR-001 clinical program

Read original article